October 06, 2009
In rejecting a bid by generic-drug divisions of pharmaceutical company URL Pharma Inc. to get state law tort claims over the anti-inflammatory Sulindac dismissed by arguing that the claims are preempted by federal law, a New Hampshire federal judge has joined the ranks of courts that have rejected the preemption argument in a generic-drug liability case.